Emergence of Resistance to Azithromycin‐Atovaquone in Immunocompromised Patients withBabesia microtiInfection | Zendy

Gary P. Wormser | Zendy; Aakanksha Prasad | Zendy; Ellen Neuhaus | Zendy; Samit R. Joshi | Zendy; John Nowakowski | Zendy; John C. Nelson | Zendy; Abraham Mittleman | Zendy; Maria AgueroRosenfeld | Zendy; Jeffrey Topal | Zendy; Peter J. Krause | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emergence of Resistance to Azithromycin‐Atovaquone in Immunocompromised Patients withBabesia microtiInfection

Author(s) -

Gary P. Wormser,

Aakanksha Prasad,

Ellen Neuhaus,

Samit R. Joshi,

John Nowakowski,

John C. Nelson,

Abraham Mittleman,

Maria AgueroRosenfeld,

Jeffrey Topal,

Peter J. Krause

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/649859

Subject(s) - atovaquone , virology , medicine , azithromycin , babesiosis , babesia , microbiology and biotechnology , immunology , malaria , biology , antibiotics , plasmodium falciparum

Babesiosis is an emerging tickborne malaria-like infection principally caused by Babesia microti. This infection typically resolves either spontaneously or after administration of a 7-10-day course of azithromycin plus atovaquone or clindamycin plus quinine. Although certain highly immunocompromised patients may respond suboptimally to these drug regimens, unlike the situation with malaria there has been no reported evidence that the cause of treatment failure is infection with drug-resistant strains of B. microti.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research